1. Academic Validation
  2. Novel isoindoline compounds for potent and selective inhibition of prolyl dipeptidase DPP8

Novel isoindoline compounds for potent and selective inhibition of prolyl dipeptidase DPP8

  • Bioorg Med Chem Lett. 2005 Feb 1;15(3):687-91. doi: 10.1016/j.bmcl.2004.11.023.
Weir-Torn Jiaang 1 Yuan-Shou Chen Tsu Hsu Ssu-Hui Wu Chia-Hui Chien Chung-Nien Chang Sheng-Ping Chang Shiow-Ju Lee Xin Chen
Affiliations

Affiliation

  • 1 Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 161, Sec. 6, Minchiuan E. Rd., Neihu, Taipei 114, Taiwan, ROC. [email protected]
Abstract

DPP8 is a prolyl dipeptidase homologous to DPP-IV, which is a drug target for Type II diabetes. The biological function of DPP8 is not known. To identify potent and selective chemical compounds against DPP8, we have synthesized a series of isoquinoline and isoindoline derivatives and have tested their inhibitory activity against DPP8, DPP-IV and DPP-II. Isoindoline derivatives were found to be more potent DPP8 inhibitors than isoquinoline derivatives. Isoindoline with a 1-(4,4'-difluor-benzhydryl)-piperazine group at the P2 site was observed to be a very potent DPP8 inhibitor, having an IC(50) value of 14nM with at least a 2500-fold selectivity over either DPP-IV or DPP-II. From SAR results, we speculate that the S1 site of DPP8 may be larger than that of DPP-IV, which would allow the accommodation of larger C-terminal residues, such as isoquinoline or isoindoline.

Figures